Nightstar Therapeutics (NITE) PT Raised to $36 at Wedbush

Go back to Nightstar Therapeutics (NITE) PT Raised to $36 at Wedbush

Nightstar Reports Positive Proof of Concept Data from Dose Escalation Study in XIRIUS Trial for NSR-RPGR in XLRP Patients

September 22, 2018 11:58 AM EDT

NSR-RPGR data presented at EURETINA 2018 Congress demonstrated proof of concept with durable dose-related improvements seen as early as month 1 across multiple microperimetry analyses

Preliminary efficacy signals observed in 3/3 patients in cohort 3 and 2/6 patients in cohorts 4 and 5, including durable improvements in overall macula sensitivity, central 16 macula sensitivity and number of improved macula loci

NSR-RPGR was well-tolerated with no dose limiting toxicities or serious treatment-related adverse events

XIRIUS expansion study planned to initiate in Q4 2018

Detailed results to be presented at R&D day... More

Nightstar Reports Positive Proof of Concept Data from Dose Escalation Study in XIRIUS Trial for NSR-RPGR in XLRP Patients

September 22, 2018 11:57 AM EDT

NSR-RPGR data presented at EURETINA 2018 Congress demonstrated proof of concept with durable dose-related improvements seen as early as month 1 across multiple microperimetry analyses

Preliminary efficacy signals observed in 3/3 patients in cohort 3 and 2/6 patients in cohorts 4 and 5, including durable improvements in overall macula sensitivity, central 16 macula sensitivity and number of improved macula loci

NSR-RPGR was well-tolerated with no dose limiting toxicities or serious treatment-related adverse events

XIRIUS expansion study planned to initiate in Q4 2018

Detailed results to be presented at R&D day on... More